NewMed Energy - Limited Partnership (NWMD) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of NewMed Energy - Limited Partnership ILS 17.60, price ILS 15.76, upside +11.7%, quality 59 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range 3.25 ILA – 21.76 ILA · fair‑value band 8.31 ILA – 30.08 ILA · the 15.76 ILA price screens below the 17.60 ILA fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow NewMed Energy - Limited Partnership in your weekly email
Every Wednesday you see whether NewMed Energy - Limited Partnership is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
NewMed Energy - Limited Partnership exploration, development, production, and marketing of natural gas, condensate, and oil in Israel, Jordan and Egypt.
Show more
NewMed Energy - Limited Partnership exploration, development, production, and marketing of natural gas, condensate, and oil in Israel, Jordan and Egypt. The company holds interests in the Leviathan project, which covers an area of 500 square kilometer (km2) located to the west of the shores of Haifa; the Block 12 that covers an area of approximately 386 km2 located in Cyprus; and the Yam Tethys project, located to the west of the shores of Ashkelon. It also holds interests in the Boujdour Atlantique exploration license that covers an area of approximately 33,815 km2 located in the south of the Moroccan exclusive economic zone; and the Tanin and Karish leases covering an area of approximately 500km2 located to the west of the shores of Nahariya. The company serves independent power producers, marketing companies, and industrial customers, as well as exports natural gas to Jordan and in Egypt. The company was formerly known as Delek Drilling - Limited Partnership and changed its name to NewMed Energy - Limited Partnership in February 2022. NewMed Energy - Limited Partnership was incorporated in 1993 and is based in Herzliya, Israel.
Stock analysis
NewMed Energy - Limited Partnership (NWMD) currently trades at 15.76 ILA, while our model-based Fair Value estimate is 17.60 ILA, implying the stock looks roughly 10.5% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 20.26 ILA per share, and 10 of the 25 models we run sit above the 15.76 ILA price.
Bear case: the Asset-Based group reads lowest at 3.29 ILA, and 15 of the 25 models stay below the price. Evidence for this calculation is high.
Scenario range: 8.31 ILA (bear) to 30.08 ILA (bull), the price of 15.76 ILA sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 59/100 (solid quality), in the Energy sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
NewMed Energy - Limited Partnership reported revenue of $938M in FY2025 versus $883M in FY2021, a compound +1.5%/yr. Reported net income was $371M in FY2025, compounding −2.1%/yr from FY2021.
Key figures
Market cap 18.5B ILA · P/E ratio 22.5 · P/S ratio 8.91 · EPS (TTM) 0.7000 ILA · Dividend yield 1.4% · Net margin 39.6% · Return on equity 14.5% · Return on assets (EBIT) 15.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 28% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Energy peers we cover trades at 10% fair-value upside, at 12%, NWMD screens cheaper than that median.
Fair Value models
Bear 8.31 ILAFair Value 17.60 ILABull 30.08 ILA
Price 15.76 ILA · Upside +11.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.3709 ILS per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−17.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.8%
Start year 2020 (pandemic). Over 10 years: +14.3% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+1.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+0.3%
Dividend (yield on the price)1.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.0.3% vs 8.9%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.52% → 60%
Start year 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+14.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +11.3% a year for the price.
News mood ⓘNews mood, the average tone of recent news (34 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
Compare NewMed Energy - Limited Partnership with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Oil & Gas E&P · 278 stocks
Beats the industry median on 7/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score59 · Top 25%
Fair Value upside+11.7% · Above median
Profitability
Return on equity (TTM)14.5% · Top 25%
Return on assets6.4% · Above median
Net margin (TTM)31.1% · Top 25%
Operating margin (TTM)70.1% · Top 25%
Growth and dividend
Revenue growth52.5% · Top 25%
Dividend yield (TTM)1.4% · Bottom 25%
Balance sheet
Debt / equity0.74× · Highest 25%
Valuation Multiplesvs Oil & Gas E&P median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "NewMed Energy - Limited Partnership Fair Value". https://www.fairvalue-calculator.com/stock/NWMD
Frequently asked questions
Is NewMed Energy - Limited Partnership (NWMD) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of 17.60 ILA versus a price of 15.76 ILA, about +12% upside (undervalued).
What is the fair value of NWMD?
Our model-based fair value for NewMed Energy - Limited Partnership is 17.60 ILA (as of Sep 27, 2026), built from audited fundamentals. The current price: 15.76 ILA.
What is the quality score of NWMD?
NewMed Energy - Limited Partnership has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for NewMed Energy - Limited Partnership (NWMD)?
Our model-based price target is the fair value of 17.60 ILA (as of Sep 27, 2026) from 26 valuation models. Cautious scenario 8.31 ILA, optimistic scenario 30.08 ILA. It is a calculation from audited fundamentals, not an analyst target.
What is the NewMed Energy - Limited Partnership stock forecast for 2026?
Our models put fair value at 17.60 ILA, about +12% upside versus a price of 15.76 ILA (undervalued). Cautious scenario 8.31 ILA, optimistic scenario 30.08 ILA. The calculation is refreshed regularly with new filings.
What is the revenue of NewMed Energy - Limited Partnership (NWMD)?
NewMed Energy - Limited Partnership reported trailing-twelve-month revenue of about $848M (latest available figure, as of Sep 27, 2026).
Does NewMed Energy - Limited Partnership pay a dividend?
NewMed Energy - Limited Partnership currently shows a dividend yield of about 1.35% relative to its recent price (as of Sep 27, 2026).
What growth is priced into NewMed Energy - Limited Partnership (NWMD)?
For today's price to be fair in a discounted-cash-flow model, NewMed Energy - Limited Partnership would have to grow free cash flow by +14.0 % per year for five years (discount rate 10.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +9.8 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of NWMD use?
Our models discount NewMed Energy - Limited Partnership at 10.1 %: a base by market capitalisation (mid), damped by beta 0.40, country premium for Israel. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For NewMed Energy - Limited Partnership that is +14.0 % per year a year over ten years, using the same discount rate (10.1 %) and the same formula as our fair value.
How much growth has NewMed Energy - Limited Partnership (NWMD) delivered so far?
Over the past 5 years revenue at NewMed Energy - Limited Partnership grew +9.8 % a year. The price currently implies +14.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of NewMed Energy - Limited Partnership (NWMD) growing?
The median revenue growth in the sector is +11.2 % a year. That is the yardstick for the growth priced into NewMed Energy - Limited Partnership (+14.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of NewMed Energy - Limited Partnership (NWMD)?
The free-cash-flow yield on the price is 5.02 %: that much free cash flow NewMed Energy - Limited Partnership produces per unit of market value. When it exceeds the discount rate of our models (10.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of NewMed Energy - Limited Partnership (NWMD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For NewMed Energy - Limited Partnership it is 17.60 ILA per share (as of Sep 27, 2026), against a price of 15.76 ILA. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is NewMed Energy - Limited Partnership stock overvalued or undervalued in 2026?
As of Sep 27, 2026, NWMD trades below its calculated fair value: price 15.76 ILA, fair value 17.60 ILA, a gap of about +12% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NWMD?
No. The price is what the market pays today (15.76 ILA); the fair value is what the company's own numbers justify (17.60 ILA). For NewMed Energy - Limited Partnership the two are 1.84 ILA per share apart. That gap is exactly why we show both numbers side by side.
How much is NewMed Energy - Limited Partnership worth?
The market values NewMed Energy - Limited Partnership at about 18.5B ILA (market capitalisation, as of Sep 27, 2026). Per share that is 15.76 ILA; our models calculate a fair value of 17.60 ILA per share.
What do the bullish and bearish scenarios say about NWMD?
Our models span a range for NewMed Energy - Limited Partnership: cautious scenario 8.31 ILA, base 17.60 ILA, optimistic 30.08 ILA per share (as of Sep 27, 2026, price 15.76 ILA). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of NWMD?
NewMed Energy - Limited Partnership trades at a price-to-earnings ratio of 22.5 (as of Sep 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 17.60 ILA is built from several models across several years. Other multiples: P/B 3.2, P/S 7.2, EV/EBITDA 11.0.
How solid is the balance sheet of NewMed Energy - Limited Partnership (NWMD)?
Balance-sheet figures for NewMed Energy - Limited Partnership (as of Sep 27, 2026): return on equity 14.5%, debt of 0.74 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is NWMD from its 52-week high?
NewMed Energy - Limited Partnership trades at 15.76 ILA, about 28% below its 52-week high of 21.76 ILA and 3% above the low of 15.31 ILA (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of 17.60 ILA is for.
Which stocks are comparable to NewMed Energy - Limited Partnership?
From the same area (Energy) we also value ConocoPhillips explores for,, CNOOC Limited, Canadian Natural Resources Limited, EOG Resources, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is NewMed Energy - Limited Partnership stock attractive at the current price?
The data as of Sep 27, 2026: price 15.76 ILA, calculated fair value 17.60 ILA (+12%), Quality Score 59/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NWMD calculated?
We run NewMed Energy - Limited Partnership through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 17.60 ILA, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. NewMed Energy - Limited Partnership currently trades 10 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of NewMed Energy - Limited Partnership (NWMD)?
The closing price on Oct 1, 2026 was 15.76 ILA. Our model-based fair value is 17.60 ILA, about +12% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with NewMed Energy - Limited Partnership right now?
The model range is unusually wide (8.31 ILA to 30.08 ILA). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of NewMed Energy - Limited Partnership (NWMD) come from?
Earnings per share at NewMed Energy - Limited Partnership grew +10.8 % a year from 2014 to 2025. Broken into its drivers: revenue per share +11.1 %, EBIT margin +2.3 %, tax rate −2.9 %, residual (interest, one-offs) +0.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of NewMed Energy - Limited Partnership
How large is the market capitalisation of NewMed Energy - Limited Partnership (NWMD)?
The market capitalisation of NewMed Energy - Limited Partnership is 18.5B ILA. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of NewMed Energy - Limited Partnership (NWMD)?
The price-to-sales ratio of NewMed Energy - Limited Partnership is 8.91 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of NewMed Energy - Limited Partnership (NWMD)?
Earnings per share at NewMed Energy - Limited Partnership are 0.7000 ILA (price ÷ EPS = P/E 22.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of NewMed Energy - Limited Partnership (NWMD)?
The dividend yield of NewMed Energy - Limited Partnership is 1.4% (payout 30.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of NewMed Energy - Limited Partnership (NWMD)?
The net margin of NewMed Energy - Limited Partnership is 39.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of NewMed Energy - Limited Partnership (NWMD)?
The return on equity (ROE) of NewMed Energy - Limited Partnership is 14.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of NewMed Energy - Limited Partnership (NWMD)?
On an EBIT basis the return on assets of NewMed Energy - Limited Partnership is 15.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of NewMed Energy - Limited Partnership (NWMD)?
The operating margin of NewMed Energy - Limited Partnership is 70.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at NewMed Energy - Limited Partnership (NWMD)?
Revenue at NewMed Energy - Limited Partnership is growing +52.5% versus a year earlier (3y avg −6.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at NewMed Energy - Limited Partnership (NWMD)?
Earnings per share at NewMed Energy - Limited Partnership are growing +45.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does NewMed Energy - Limited Partnership (NWMD) carry?
The net debt of NewMed Energy - Limited Partnership is $1.0B (fiscal year 2025, ≈ 3.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch NewMed Energy - Limited Partnership in the live analysis
One click puts NewMed Energy - Limited Partnership on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
